Maxim downgraded NeuroSense (NRSN) to Hold from Buy.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRSN:
- NeuroSense Receives FDA Approval for Phase 3 Study of ALS Treatment
- NeuroSense concludes Type C meeting with FDA for PrimeC treatment
- NeuroSense files to sell 6.6M ordinary shares for holders
- NeuroSense’s PrimeC Shows Promise in ALS Treatment
- NeuroSense announces ‘positive’ results from the PARADIGM study